Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Mainz BioMed NV

< Previous 1 2 Next >
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
Tickers ASX:MAP MYNZ
Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Secures up to $50M in New Funding
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Expands into Romania Through Partnership with Bioclinica
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Expands Commercial Footprint into Poland
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
From Mainz BioMed NV
Via GlobeNewswire
Tickers ASX:MAP MYNZ
Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed to Participate in Digestive Disease Week 2023
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.